publication . Article . 2020

The first experience with Angiovit in the combination treatment of acute COVID-19 infection

Aleksey Nikolaevich Boyko; N. A. Shamalov; O. V. Boyko; E. E. Arinina; O. V. Lyang; E. A. Dubchenko; A. V. Ivanov; A. A. Kubatiev;
Open Access
  • Published: 25 Jun 2020 Journal: Neurology, Neuropsychiatry, Psychosomatics, volume 12, pages 82-86 (issn: 2074-2711, eissn: 2310-1342, Copyright policy)
  • Publisher: IMA Press, LLC
On March 11, 2020, the WHO announced the COVID-19 outbreak a pandemic. The disease was established to be caused by a new singlestranded RNA virus (ss-RNA, 29903 bp) that belongs to a group of coronaviruses (CoV). Objective : to assess the results of a pilot analysis of the efficiency of using Angiovit in the combination treatment of acute COVID-19 with pneumonia or acute respiratory viral infection. Patients and methods . The study enrolled 50 patients with acute COVID-19. In all the patients, the diagnosis of coronavirus infection was confirmed by polymerase chain reaction. Angiovit was used in 25 patients (13 (52%) women) (mean age, 39.4 years) with moderate i...
Persistent Identifiers
free text keywords: covid-19, treatment, angiitis, folic acid, Outbreak, Coronavirus disease 2019 (COVID-19), Pandemic, Internal medicine, medicine.medical_specialty, medicine, business.industry, business, Combined treatment, Combination therapy, Coronavirus, medicine.disease_cause, Folic acid, Disease, lcsh:Neurology. Diseases of the nervous system, lcsh:RC346-429
Related Organizations
Any information missing or wrong?Report an Issue